How to appeal a CareFirst BCBS chronic wound care denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for chronic wound care

Cited policy: BCBS Medical Policy: Bioengineered Skin and Soft Tissue Substitutes (BCBSA Ref. )

Patterned on CMS LCD L35041: dehydrated human amnion-chorion membrane (dHACM, EpiFix Q4186) for DFU or VLU >=4 weeks failed standard care, ABI >=0.65, no untreated osteomyelitis or active deep infection, <50% area reduction with conventional therapy. Up to 8-10 applications per episode with documented progress. Vascular workup required before initiation.

How CareFirst BCBS denies chronic wound care — and how to counter it

Where CareFirst BCBS pushes back: 1) Use cheaper CTP first (Apligraf / Dermagraft); 2) Insufficient evidence vs SOC; 3) >5 applications excessive; 4) Provider not specialty-credentialed.

Counter-arguments that hold up: Cite Zelen Int Wound J 2013;10(5):502-507 (DFU N=25 healing 92% dHACM vs 8% standard care, p<0.001 — fastest published DFU healing rate) + Zelen Int Wound J 2015;12(6):724-732 (head-to-head dHACM vs Apligraf vs SOC; dHACM superior at 4 + 6 wk closure) + Serena Vasc Endovasc Surg 2014 (VLU). HCPCS Q4186 reimbursed under standard ASP+6% — formulary tier preference cannot override medical necessity. CMS LCD L35041 does not mandate failure of one CTP before another; physician selects based on wound characteristics, depth, exudate, and prior history.

What CareFirst BCBS typically denies for chronic wound care

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For chronic wound care, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the chronic wound care treatments most often flagged for prior auth, step therapy, or medical necessity review:

• HBOT
• NPWT (wound vac)
• Apligraf
• Dermagraft
• EpiFix (dHACM)
• Grafix

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.